Prescription drug · NDA
Tavalisse (Fostamatinib) NDC 71332-002
Fostamatinib 150 mg/1 · Tablet · Oral · Rigel Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71332-002-01 | 71332000201 | 60 TABLET in 1 BOTTLE (71332-002-01)Marketed from May 9, 2018 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Tavalisse
- Generic name (nonproprietary)
- fostamatinib
- Active ingredients
- Fostamatinib — 150 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Rigel Pharmaceuticals, Inc.NDC labeler code 71332
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 209299
- Marketing start
- Listing expires
- Identifiers
- Product ID 71332-002_78828503-b88f-4e3d-9add-8b738c4cf28eSPL ID 78828503-b88f-4e3d-9add-8b738c4cf28eSPL set ID 21149cc3-049b-43e2-b141-c9499160556cRxCUI 2044922, 2044928, 2044930, 2044932UNII SQ8A3S5101
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N471332000201followed by a unit qualifier and the quantityPackage 71332-0002-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Excerpt only. Read the full label for complete information.
About NDC 71332-002
- What is NDC 71332-002?
- 71332-002 is the product NDC for Tavalisse (fostamatinib), Fostamatinib 150 mg/1 tablet, listed with the FDA by Rigel Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Tavalisse (Fostamatinib).
- What is the active ingredient?
- Fostamatinib.
- Who is the labeler?
- Rigel Pharmaceuticals, Inc., NDC labeler code 71332. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Tavalisse?
- 1 other product NDC are listed under this name. See all Tavalisse NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Tavalisse products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Tavalissefostamatinib | Fostamatinib 100 mg/1 | TabletOral | Rigel Pharmaceuticals, Inc. | 71332-001 | 71332-0001-01 |
Other NDCs under NDA 209299
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Tavalissefostamatinib | Fostamatinib 100 mg/1 | TabletOral | Rigel Pharmaceuticals, Inc. | 71332-001 |